Quetiapine treatment of children and adolescents with Tourette's disorder.
OBJECTIVE
The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder.


METHODS
This was an 8-week, open-label trial that included 12 subjects with a mean age of 11.4 +/- 2.4 years. The subjects were seen every week throughout the study.


RESULTS
Clinical responses, as measured by the Turkish version of the Yale Global Tic Severity Scale, revealed a statistically significant reduction in tic scores ranging from 30-100%. Mean dose of quetiapine at the end of the study was 72.9 +/- 22.5 mg/day. Three subjects complained of sedation in the first week of treatment.


CONCLUSIONS
The favorable results of this open-label study should be interpreted with caution due to the uncontrolled nature of the study. Spontaneous waxing and waning of symptoms should also be considered. Further controlled studies are required.
Mukaddes
Nahit Motavali
NM
Istanbul University, Child and Adolescent Psychiatry Department, Medical Faculty of Istanbul, Istanbul, Turkey. nmotavalli@yahoo.com
Abali
Osman
O
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000523:psychology
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate